Cargando…

Pegylated liposomal doxorubicin in the management of ovarian cancer

Among the pharmaceutical options available for treatment of ovarian cancer, much attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation, which entraps conventional doxorubicin in a bilayer lipidic sphere surrounded by a polyethylene glycol layer,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrandina, Gabriella, Corrado, Giacomo, Licameli, Angelo, Lorusso, Domenica, Fuoco, Gilda, Pisconti, Salvatore, Scambia, Giovanni
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952486/ https://www.ncbi.nlm.nih.gov/pubmed/20957139 http://dx.doi.org/10.2147/TCRM.S3348

Ejemplares similares

Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
por: Adamo, V, et al.
Publicado: (2008)

Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report
por: Corrado, Giacomo, et al.
Publicado: (2010)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer
por: D'Agostino, G, et al.
Publicado: (2003)

Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
por: Legge, Francesco, et al.
Publicado: (2011)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
por: Legge, Francesco, et al.
Publicado: (2008)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
por: Markman, Maurie
Publicado: (2011)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer
por: Pignata, Sandro, et al.
Publicado: (2021)

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
por: Pignata, S, et al.
Publicado: (2007)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Femur metastasis in carcinoma of the uterine cervix: a rare entity
por: Corrado, Giacomo, et al.
Publicado: (2009)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2015)

Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma
por: Mazzotta, Marco, et al.
Publicado: (2016)

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
por: Staropoli, Nicoletta, et al.
Publicado: (2013)

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
por: Jones, Robin L., et al.
Publicado: (2021)

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
por: Li, Xin-Ru, et al.
Publicado: (2022)

Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
por: Coldiron, Matthew E., et al.
Publicado: (2021)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis
por: Mantegna, Giovanna, et al.
Publicado: (2013)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
por: Shah, Jatin J, et al.
Publicado: (2009)

Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
por: Marczak, Agnieszka, et al.
Publicado: (2014)

The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials
por: Li, Xin-Ru, et al.
Publicado: (2021)

Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both
por: Bonaca, Marc P, et al.
Publicado: (2023)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
por: Cainelli, Francesca, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022)

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
por: Takahashi, Shunji, et al.
Publicado: (2021)

Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma
por: Nik, Maryam Ebrahimi, et al.
Publicado: (2019)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7efauollpanh1ah5srijr287to